key: cord-0857471-9vwoji5l
authors: Watanabe, Hanako; Ashida, Miwa; Satomi, Naoyoshi; Koike, Yuta; Kuwatsuka, Sayaka; Murota, Hiroyuki
title: Histopathological analysis of skin reactions after coronavirus disease 2019 vaccination: Increment in number of infiltrated plasmacytoid dendritic cell
date: 2022-04-04
journal: J Dermatol
DOI: 10.1111/1346-8138.16374
sha: c1679c12d064914477d71088281bc7269f8d26ef
doc_id: 857471
cord_uid: 9vwoji5l

Skin disorders are frequent adverse events after coronavirus disease 2019 (COVID‐19) vaccination. However, the pathogenesis of these disorders is not fully understood. Here, we report a case series of cutaneous adverse events following COVID‐19 vaccination, and the results of our investigation reveal the underlying mechanism. Case 1: a 47‐year‐old female developed a wheal, confined to the COVID‐19 vaccination site, 2 days after her first injection. She was treated with topical steroids and oral antihistamines. Case 2: a 51‐year‐old female showed generalized petechial erythema accompanied by fever, genital bleeding, thrombocytopenia, liver dysfunction, and disseminated intravascular coagulation, 2 days after her second injection. She was diagnosed with vaccine‐induced macrophage activation syndrome and treated with anti‐inflammatory therapy. Immunohistological analysis of the skin eruption, in both these cases, showed infiltration of CD123(+) BDCA2(+) plasmacytoid dendritic cells (p‐DC). Despite the distinctive clinical features in these two cases, this finding suggests that p‐DC might be involved in different cutaneous adverse events after COVID‐19 vaccination.

other complicating symptoms (Figure 1a) . She was treated with topical betamethasone butyrate propionate and systemic fexofenadine hydrochloride. The skin disorder disappeared 9 days after the inoculation, and she received the second vaccination dose without experiencing further adverse events.

A 51-year-old female without past medical history received the initial dose of BNT162b2, i.m., in her deltoid region. Two days after the first injection, she noticed genital bleeding. Two days after the second injection, she again experienced genital bleeding accompanied by a fever of 38.3°C. She was admitted to hospital with thrombocytopenia and petechial erythema (Figure 1b,c) The patient was diagnosed with disseminated intravascular coagulation (DIC) according to genital bleeding, thrombocytopenia, and elevated fibrinogen degradation products. Ferritin was also elevated at 11 970 ng/dL, but adult Still's disease was ruled out because of a lack of spike fever or arthralgia. Antinuclear antibodies and rheumatoid factor were both negative, and there was no genetic mutation in MEFV, NLRP3, TNFAIP3, MVK, or TNFRSF1A, which are genes responsible for autoinflammatory diseases. Finally, the patient was considered to have macrophage activation syndrome (MAS) in which vaccination triggered excessive cytokine production. Consequently, she was administered both high-dose intravascular immunoglobulin therapy and i.v. administration of methylprednisolone sodium succinate. During the next 3 days, her fever subsided and the skin manifestation disappeared.

Histopathological analysis was performed of a skin sample of the local injection site and erythema of the right dorsal hand, distant from the local injection site, derived from cases 1 and 2, respectively. Therefore, we initially anticipated that the pathological findings of Indeed, myxovirus-resistance protein 1-exposed skin-derived IFN-I is a cause of skin disorder after COVID-19 vaccination. 10 In the present cases, we performed staining for CD123 and 

Domestic situation, Ministry of Health, Labor and Welfare of Japan

Ongoing Topics, Novel Coronavirus Vaccines, Prime Minister of Japan and His Cabinet

Health sciences council (vaccination and vaccine subcommittee meeting Associate reaction consideration section), Ministry of Health, Labor and Welfare of Japan

SARS-CoV-2 endothelial infection causes COVID-19 chilblains: histopathological, immunohistochemical and ultraestructural study of 7 paediatric cases

SARS-CoV-2 spike protein positivity in pityriasis rosea-like and urticaria-like rashes of COVID-19

Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases

Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: a registry based study

Immune responses induced by mRNA vaccination in mice, monkeys and humans. Vaccines (Basal)

COVID-19 vaccine side effects: the positives about feeling bad

Clinical and histopathological views of morbilliform rash after COVID-19 mRNA vaccination mimic those in SARS-CoV-2 virus infection-associated cutaneous manifestations

Numerous plasmacytoid dendritic cell infiltration in HIV-associated psoriasis relieved only with antiretroviral therapy

COVID toes"): histologic, immunofluorescence, and immunohistochemical study of 17 cases

Histopathological analysis of skin reactions after coronavirus disease 2019 vaccination: Increment in number of infiltrated plasmacytoid dendritic cell